Three Years of the Gefitinib UK Single Patient Access (SPA) Scheme- Duration of Treatment for Patients with EGFR Mutation Positive NSCLC in NHS Clinical Practice
Abstract
Authors
H. Vioix S. Franzen D. Selby D. Collomb O. Hauch C. Emmas